Efficacy and safety of apremilast in patients with moderate-to-severe plaque psoriasis of the scalp: results up to 32 weeks from a randomized, phase III study

A. S. Van Voorhees; L. Stein Gold; M. Lebwohl; B. Strober; H. Sofen; K. Papp; J. Bagel; Z. Zhang; M. Paris; Y. Wang

doi:10.1111/bjd.20083

Efficacy and safety of apremilast in patients with moderate-to-severe plaque psoriasis of the scalp: results up to 32 weeks from a randomized, phase III study

A. S. Van Voorhees, L. Stein Gold, M. Lebwohl, B. Strober, H. Sofen, K. Papp, J. Bagel, Z. Zhang, M. Paris, Y. Wang

Research output: Contribution to journal › Letter › peer-review

2 Scopus citations

Original language	English
Pages (from-to)	840-842
Number of pages	3
Journal	British Journal of Dermatology
Volume	185
Issue number	4
DOIs	https://doi.org/10.1111/bjd.20083
State	Published - Oct 2021

Access to Document

10.1111/bjd.20083

Cite this

Van Voorhees, A. S., Stein Gold, L., Lebwohl, M., Strober, B., Sofen, H., Papp, K., Bagel, J., Zhang, Z., Paris, M., & Wang, Y. (2021). Efficacy and safety of apremilast in patients with moderate-to-severe plaque psoriasis of the scalp: results up to 32 weeks from a randomized, phase III study. British Journal of Dermatology, 185(4), 840-842. https://doi.org/10.1111/bjd.20083

@article{ed2bcda433d443548efb8f62398dbb1c,

title = "Efficacy and safety of apremilast in patients with moderate-to-severe plaque psoriasis of the scalp: results up to 32 weeks from a randomized, phase III study",

author = "{Van Voorhees}, {A. S.} and {Stein Gold}, L. and M. Lebwohl and B. Strober and H. Sofen and K. Papp and J. Bagel and Z. Zhang and M. Paris and Y. Wang",

note = "Funding Information: Writing support was funded by Amgen Inc. and provided by Amy Shaberman PhD, of Peloton Advantage LLC, an OPEN Health Company, Parsippany, NJ, USA. Funding Information: sources: This study was funded by Celgene. Amgen acquired the worldwide rights to Otezla? (apremilast) on 21 November 2019.Writing support was funded by Amgen Inc. and provided by Amy Shaberman PhD, of Peloton Advantage LLC, an OPEN Health Company, Parsippany, NJ, USA.",

year = "2021",

month = oct,

doi = "10.1111/bjd.20083",

language = "English",

volume = "185",

pages = "840--842",

journal = "British Journal of Dermatology",

issn = "0007-0963",

publisher = "Wiley-Blackwell Publishing Ltd",

number = "4",

}

Van Voorhees, AS, Stein Gold, L, Lebwohl, M, Strober, B, Sofen, H, Papp, K, Bagel, J, Zhang, Z, Paris, M & Wang, Y 2021, 'Efficacy and safety of apremilast in patients with moderate-to-severe plaque psoriasis of the scalp: results up to 32 weeks from a randomized, phase III study', British Journal of Dermatology, vol. 185, no. 4, pp. 840-842. https://doi.org/10.1111/bjd.20083

TY - JOUR

T1 - Efficacy and safety of apremilast in patients with moderate-to-severe plaque psoriasis of the scalp

T2 - results up to 32 weeks from a randomized, phase III study

AU - Van Voorhees, A. S.

AU - Stein Gold, L.

AU - Lebwohl, M.

AU - Strober, B.

AU - Sofen, H.

AU - Papp, K.

AU - Bagel, J.

AU - Zhang, Z.

AU - Paris, M.

AU - Wang, Y.

N1 - Funding Information: Writing support was funded by Amgen Inc. and provided by Amy Shaberman PhD, of Peloton Advantage LLC, an OPEN Health Company, Parsippany, NJ, USA. Funding Information: sources: This study was funded by Celgene. Amgen acquired the worldwide rights to Otezla? (apremilast) on 21 November 2019.Writing support was funded by Amgen Inc. and provided by Amy Shaberman PhD, of Peloton Advantage LLC, an OPEN Health Company, Parsippany, NJ, USA.

PY - 2021/10

Y1 - 2021/10

UR - http://www.scopus.com/inward/record.url?scp=85114337639&partnerID=8YFLogxK

U2 - 10.1111/bjd.20083

DO - 10.1111/bjd.20083

M3 - Letter

C2 - 33763874

AN - SCOPUS:85114337639

SN - 0007-0963

VL - 185

SP - 840

EP - 842

JO - British Journal of Dermatology

JF - British Journal of Dermatology

IS - 4

ER -